Skip to main content
Journal ArticleOPEN ACCESS

Sclerostin

  • Silverman S
Journal of Osteoporosis (2010) 2010 1-3
DOI: 10.4061/2010/941419
N/ACitations
Citations of this article
63Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. One potential new agent is monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis.

Cite

CITATION STYLE

APA

Silverman, S. L. (2010). Sclerostin. Journal of Osteoporosis, 2010, 1–3. https://doi.org/10.4061/2010/941419

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free